AP766A - A vaccine based on hepatitis B antigen. - Google Patents
A vaccine based on hepatitis B antigen. Download PDFInfo
- Publication number
- AP766A AP766A APAP/P/1997/001060A AP9701060A AP766A AP 766 A AP766 A AP 766A AP 9701060 A AP9701060 A AP 9701060A AP 766 A AP766 A AP 766A
- Authority
- AP
- ARIPO
- Prior art keywords
- hepatitis
- vaccine
- hbsag
- antigen
- vaccine composition
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 41
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 28
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 title claims description 6
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 239000000427 antigen Substances 0.000 claims abstract description 32
- 102000036639 antigens Human genes 0.000 claims abstract description 32
- 108091007433 antigens Proteins 0.000 claims abstract description 32
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract description 14
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 11
- 208000006454 hepatitis Diseases 0.000 claims description 10
- 231100000283 hepatitis Toxicity 0.000 claims description 10
- 229940029583 inactivated polio vaccine Drugs 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 241000700721 Hepatitis B virus Species 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 206010043376 Tetanus Diseases 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 206010013023 diphtheria Diseases 0.000 claims description 4
- 208000005252 hepatitis A Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 102100031673 Corneodesmosin Human genes 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 101710137302 Surface antigen S Proteins 0.000 claims description 3
- 229940001007 aluminium phosphate Drugs 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 230000004224 protection Effects 0.000 claims description 3
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 229940096437 Protein S Drugs 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 239000011246 composite particle Substances 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000002245 particle Substances 0.000 description 7
- 229960002520 hepatitis vaccine Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 6
- 229960004906 thiomersal Drugs 0.000 description 6
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229940124884 Engerix-B Drugs 0.000 description 4
- 229940001442 combination vaccine Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229910001679 gibbsite Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940124914 Havrix Drugs 0.000 description 1
- 206010057212 Hepatitis viral infections Diseases 0.000 description 1
- 229940124915 Infanrix Drugs 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007689 endotoxicity Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9503863.4A GB9503863D0 (en) | 1995-02-25 | 1995-02-25 | Vaccine compositions |
| PCT/EP1996/000681 WO1996026741A1 (en) | 1995-02-25 | 1996-02-15 | Hepatitis b vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9701060A0 AP9701060A0 (en) | 1997-10-31 |
| AP766A true AP766A (en) | 1999-09-17 |
Family
ID=10770292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/001060A AP766A (en) | 1995-02-25 | 1996-02-15 | A vaccine based on hepatitis B antigen. |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US5972346A (de) |
| EP (1) | EP0810877B1 (de) |
| JP (1) | JP3881015B2 (de) |
| KR (1) | KR100365373B1 (de) |
| CN (1) | CN1101225C (de) |
| AP (1) | AP766A (de) |
| AR (1) | AR002279A1 (de) |
| AT (1) | ATE209045T1 (de) |
| AU (1) | AU695921B2 (de) |
| BG (1) | BG101851A (de) |
| BR (1) | BR9607458A (de) |
| CA (1) | CA2212552C (de) |
| CZ (1) | CZ288417B6 (de) |
| DE (1) | DE69617211T2 (de) |
| DK (1) | DK0810877T3 (de) |
| EA (1) | EA199700126A1 (de) |
| ES (1) | ES2166879T3 (de) |
| FI (1) | FI118118B (de) |
| GB (1) | GB9503863D0 (de) |
| HK (1) | HK1004117A1 (de) |
| HU (1) | HU224832B1 (de) |
| IL (1) | IL117249A (de) |
| MA (1) | MA23814A1 (de) |
| MX (1) | MX9706450A (de) |
| MY (1) | MY113428A (de) |
| NO (1) | NO319394B1 (de) |
| NZ (1) | NZ302674A (de) |
| OA (1) | OA10612A (de) |
| PL (1) | PL182679B1 (de) |
| PT (1) | PT810877E (de) |
| SA (1) | SA96160633B1 (de) |
| SK (1) | SK115097A3 (de) |
| TR (1) | TR199700849T1 (de) |
| TW (1) | TW467745B (de) |
| WO (1) | WO1996026741A1 (de) |
| ZA (1) | ZA961460B (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6620414B2 (en) * | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| US6488934B1 (en) * | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| US20010014331A1 (en) * | 1996-11-07 | 2001-08-16 | Smithkline Beecham Biologicals S.A. | Acellular pertussis vaccine with diphthriae-and tetanus-toxoids |
| US20030049268A1 (en) | 1998-05-01 | 2003-03-13 | Smithkline Beecham Biologicals S.A. | Novel composition |
| GB9809507D0 (en) * | 1998-05-01 | 1998-07-01 | Smithkline Beecham Biolog | Novel composition |
| IL139813A0 (en) | 1998-05-22 | 2002-02-10 | Loeb Health Res Inst At The Ot | Methods and products for inducing mucosal immunity |
| US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| CA2773698C (en) | 1998-10-16 | 2015-05-19 | Glaxosmithkline Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
| CU22871A1 (es) * | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
| JP2002532116A (ja) * | 1998-12-23 | 2002-10-02 | メルク エンド カムパニー インコーポレーテッド | 改良された組換えｂ型肝炎表面抗原 |
| PT1187629E (pt) | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| CU23031A1 (es) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
| NZ560930A (en) * | 2005-02-16 | 2011-06-30 | Novartis Vaccines & Diagnostic | Hepatitis B virus vaccine comprising a hepatitis B virus surface antigen, aluminium phosphate, 3-O-deacylated monophosphoryl lipid A and a triethylammonium ion |
| DK1909830T3 (da) * | 2005-08-02 | 2011-12-19 | Novartis Vaccines & Diagnostic | Formindskelse af interferens mellem olieholdige adjuvanser og antigener indeholdende overfladeaktivt middel |
| CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| AU2006310337B9 (en) | 2005-11-04 | 2013-11-28 | Novartis Ag | Adjuvanted influenza vaccines including cytokine-inducing agents |
| EP1951299B1 (de) | 2005-11-04 | 2012-01-04 | Novartis Vaccines and Diagnostics S.r.l. | Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern |
| NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| CN100415294C (zh) * | 2005-12-23 | 2008-09-03 | 中国农业大学 | 一种治疗和/或预防乙肝的药物 |
| PL1976559T6 (pl) | 2006-01-27 | 2020-08-10 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy |
| EP2357184B1 (de) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazochinoxalinverbindungen als Immunmodulatoren |
| JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
| EP1862176A1 (de) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| EP1862177A1 (de) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
| US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| CA2663196A1 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
| JP2011506264A (ja) | 2006-12-06 | 2011-03-03 | ノバルティス アーゲー | インフルエンザウイルスの４つの株に由来する抗原を含むワクチン |
| SI2185191T1 (sl) | 2007-06-27 | 2012-12-31 | Novartis Ag | Cepiva proti influenci z majhnimi dodatki |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| AU2008339631B2 (en) | 2007-12-24 | 2014-07-24 | Novartis Ag | Assays for adsorbed influenza vaccines |
| HRP20220756T1 (hr) | 2009-07-15 | 2022-09-02 | Glaxosmithkline Biologicals S.A. | Proteinski pripravci rsv f i postupci za izradu istih |
| TR201908715T4 (tr) | 2011-01-26 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Rsv immünizasyon rejimi. |
| US9452212B2 (en) | 2011-04-14 | 2016-09-27 | Dynavax Technologies Corporation | Methods and compositions for eliciting an immune response against hepatitis B virus |
| PL2707385T3 (pl) | 2011-05-13 | 2018-03-30 | Glaxosmithkline Biologicals Sa | Prefuzyjne antygeny RSV F |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019780A1 (en) * | 1992-03-27 | 1993-10-14 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a |
| WO1994021292A1 (en) * | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE69031556T2 (de) * | 1989-07-25 | 1998-05-14 | Smithkline Beecham Biologicals S.A., Rixensart | Antigene sowie Verfahren zu deren Herstellung |
| CA2109714A1 (en) * | 1991-05-29 | 1992-12-10 | Frederic H. Moll | Retraction apparatus and methods for endoscopic surgery |
| PT835663E (pt) * | 1992-05-23 | 2010-01-04 | Glaxosmithkline Biolog Sa | Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios |
| GB9311536D0 (en) * | 1993-06-04 | 1993-07-21 | Unilever Plc | Hot soluble low density extractable food product |
-
1995
- 1995-02-25 GB GBGB9503863.4A patent/GB9503863D0/en active Pending
-
1996
- 1996-02-14 MY MYPI96000567A patent/MY113428A/en unknown
- 1996-02-15 AT AT96904814T patent/ATE209045T1/de active
- 1996-02-15 DK DK96904814T patent/DK0810877T3/da active
- 1996-02-15 AU AU48780/96A patent/AU695921B2/en not_active Ceased
- 1996-02-15 PT PT96904814T patent/PT810877E/pt unknown
- 1996-02-15 CN CN96192146A patent/CN1101225C/zh not_active Expired - Fee Related
- 1996-02-15 EA EA199700126A patent/EA199700126A1/ru unknown
- 1996-02-15 PL PL96321966A patent/PL182679B1/pl unknown
- 1996-02-15 KR KR1019970705880A patent/KR100365373B1/ko not_active IP Right Cessation
- 1996-02-15 NZ NZ302674A patent/NZ302674A/xx not_active IP Right Cessation
- 1996-02-15 TR TR97/00849T patent/TR199700849T1/xx unknown
- 1996-02-15 WO PCT/EP1996/000681 patent/WO1996026741A1/en active IP Right Grant
- 1996-02-15 CZ CZ19972674A patent/CZ288417B6/cs not_active IP Right Cessation
- 1996-02-15 JP JP52598896A patent/JP3881015B2/ja not_active Expired - Fee Related
- 1996-02-15 CA CA002212552A patent/CA2212552C/en not_active Expired - Fee Related
- 1996-02-15 HU HU9801242A patent/HU224832B1/hu not_active IP Right Cessation
- 1996-02-15 AP APAP/P/1997/001060A patent/AP766A/en active
- 1996-02-15 US US08/894,643 patent/US5972346A/en not_active Expired - Lifetime
- 1996-02-15 ES ES96904814T patent/ES2166879T3/es not_active Expired - Lifetime
- 1996-02-15 EP EP96904814A patent/EP0810877B1/de not_active Expired - Lifetime
- 1996-02-15 DE DE69617211T patent/DE69617211T2/de not_active Expired - Lifetime
- 1996-02-15 BR BR9607458A patent/BR9607458A/pt not_active IP Right Cessation
- 1996-02-15 SK SK1150-97A patent/SK115097A3/sk unknown
- 1996-02-22 AR ARP960101469A patent/AR002279A1/es active IP Right Grant
- 1996-02-23 MA MA24171A patent/MA23814A1/fr unknown
- 1996-02-23 ZA ZA961460A patent/ZA961460B/xx unknown
- 1996-02-23 IL IL11724996A patent/IL117249A/xx not_active IP Right Cessation
- 1996-02-26 TW TW085102154A patent/TW467745B/zh not_active IP Right Cessation
- 1996-03-02 SA SA96160633A patent/SA96160633B1/ar unknown
-
1997
- 1997-08-02 OA OA70066A patent/OA10612A/en unknown
- 1997-08-22 FI FI973457A patent/FI118118B/fi not_active IP Right Cessation
- 1997-08-22 NO NO19973873A patent/NO319394B1/no not_active IP Right Cessation
- 1997-08-22 MX MX9706450A patent/MX9706450A/es unknown
- 1997-08-25 BG BG101851A patent/BG101851A/xx unknown
-
1998
- 1998-04-28 HK HK98103600A patent/HK1004117A1/xx not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019780A1 (en) * | 1992-03-27 | 1993-10-14 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a |
| WO1994021292A1 (en) * | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP766A (en) | A vaccine based on hepatitis B antigen. | |
| CA2132833C (en) | Hepatitis vaccines containing 3-o-deacylated monophosphoryl lipid a | |
| EP0689454B1 (de) | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen | |
| US6488934B1 (en) | Hepatitis B vaccine | |
| US6620414B2 (en) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A | |
| KR20010043224A (ko) | 백신 조성물 | |
| US7144703B2 (en) | Composition | |
| CA2157376C (en) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |